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We aimed to increase our understanding of the genetic determinants of vitamin D levels by 33 
undertaking a large-scale genome-wide association study (GWAS) of serum 25 hydroxyvitamin 34 
D (25OHD). To do so, we used imputed genotypes from 401,460 white British UK Biobank 35 
participants with available 25OHD levels, retaining single nucleotide polymorphisms (SNPs) with 36 
minor allele frequency (MAF) > 0.1%, and imputation quality score > 0.3. We performed a linear 37 
mixed model GWAS on standardized log-transformed 25OHD, adjusting for age, sex, season of 38 
measurement and vitamin D supplementation. These results were combined with those from a 39 
previous GWAS including 42,274 Europeans. In silico functional follow-up of the GWAS results 40 
was undertaken to identify enrichment in gene sets, pathways and expression in tissues, and to 41 
investigate the partitioned heritability of 25OHD, and its shared heritability with other traits. Using 42 
this approach, the SNP heritability of 25OHD was estimated to 16.1%. 138 conditionally 43 
independent SNPs were detected (p-value< 6.6 x10-9) among which 53 had MAF<5%. Single 44 
variant association signals mapped to 69 distinct loci, among which 63 were novel. We identified 45 
enrichment in hepatic and lipid metabolism gene pathways, and enriched expression of the 25OHD 46 
genes in liver, skin and gastrointestinal tissues. We observed partially shared heritability between 47 
25OHD and socio-economic traits, a feature which may be mediated through time spent outdoors. 48 
Therefore, through the largest 25OHD GWAS to date, we identified 63 novel loci, which underline 49 
the contribution of genes outside the vitamin D canonical metabolic pathway to the genetic 50 
architecture of 25OHD. (250 words) 51 
 52 




Vitamin D status, as ascertained by 25-hydroxy-vitamin D level (25OHD), is associated with 55 
numerous health outcomes1. However, it is unclear if lowered 25OHD level plays a causal role in 56 
these outcomes and its exact biological mechanisms of action remains unknown2; 3. 25OHD is a 57 
steroid pro-hormone and a fat-soluble metabolite of cholecalciferol, which is predominately 58 
synthesized by exposure to ultra-violet light or obtained from dietary sources including fortified 59 
foods, supplements and oily fish. It plays an important role in regulating calcium and phosphorus 60 
concentrations and influences cell proliferation, differentiation, apoptosis and has immune 61 
modulating effects4. Understanding the etiology of low vitamin D levels could have important 62 
public health implications by prioritizing individuals who would benefit from supplementation. 63 
The body’s vitamin D stores are best reflected by serum 25OHD which is influenced not only by 64 
diet and exposure to ultra-violet light, but also by age, body mass index, skin color, and numerous 65 
factors regulating exposure to ultra-violet B radiation (including season, geographical latitude, 66 
skin coverage)5; 6. In addition to these environmental factors, classical twin studies show that 50-67 
80% of the variability in the concentration of 25OHD is explained by genetic factors7; 8 indicating 68 
that this is a highly heritable trait.  69 
 70 
In recent years, several genome-wide association studies (GWAS) of serum 25OHD have been 71 
conducted on participants of Europeans ancestry, with the largest including 79,366 individuals9. 72 
These studies have identified six common genetic variants (minor allele frequency (MAF) >5%) 73 
which are associated with 25OHD level.9-12 These variants are in loci near genes having an 74 
established role in vitamin D synthesis (DHCR7/NADSYN1 [MIM: 602858] (rs12785878) and 75 
CYP2R1 [MIM: 608713] (rs10741657)), transportation (GC [MIM: 139200] (rs2282679)) and 76 
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degradation (CYP24A1 [MIM: 126065] (rs17216707)), as well as outside of known vitamin D 77 
metabolism pathways, such as SEC23A (Sec23 homolog A, coat protein complex II component  78 
[MIM: 610511], rs8018720), involved in endoplasmic reticulum (ER)-Golgi protein trafficking, 79 
and AMDHD1 (amidohydrolase domain containing 1, rs10745742) an enzyme involved in the 80 
histidine, lysine, phenylalanine, tyrosine, proline and tryptophan catabolic pathway9. 81 
Additionally, a low frequency genetic variant (MAF <5%) at CYP2R1 (rs117913124), with a four-82 
fold larger effect than common variants at that locus was identified through whole-genome 83 
sequencing and deep imputation for low-frequency and rare variants12. 84 
 85 
An improved understanding of the genetic determinants of 25OHD has helped re-assess the role 86 
of vitamin D in the aetiology of complex diseases, such as musculoskeletal disorders 1, 87 
autoimmune disease, such as multiple sclerosis13-23 and cancer24 , through methods for causal 88 
inference, such as Mendelian randomization (MR) 25; 26. For example, four separate MR studies 89 
have supported a protective effect of vitamin D against multiple sclerosis 12-14; 27, and these results 90 
have clinical implications, reflected in recent clinical care guidelines for the use of vitamin D in 91 
preventing multiple sclerosis in those at risk, published by the MS Society of Canada28.  More than 92 
60 MR studies have been published to date utilising genetic variants associated with 25OHD to 93 
aid causal effect estimation29-46. A deeper understanding of the genetic determinants contributing 94 
to variation in circulating vitamin D levels could enable an improved instrumentation of vitamin 95 
D in MR studies, allow better genomic prediction of vitamin D levels and provide insights into 96 




Although the most recent 25OHD GWAS study on 79,366 Europeans9  had double the sample size 99 
of the previous GWASs, it yielded only two new 25OHD loci (the SEC23A and AMDHD1), 100 
indicating that 25OHD may be a metabolite with a moderately polygenic architecture. In the same 101 
study, little of the 25OHD heritability estimated using all common SNPs was explained (SNP 102 
heritability of 7.5%), suggesting that much of its heritability remains to be identified. Against this 103 
backdrop, we sought to further understand the phenotypic variance explained by genetic variants 104 
and investigate the genetic architecture of 25OHD by increasing substantially the GWAS sample 105 
size.  106 
 107 
We hypothesized that we could identify new genes encoding enzymes, or carrier proteins affecting 108 
the levels of this metabolite, unveiling a more polygenic architecture. We therefore undertook a 109 
GWAS of serum 25OHD levels in 401,460 White British individuals from UK Biobank and 110 
combined results of this GWAS in a meta-analysis with results from a previous GWAS study 111 
including up to 42,274 Europeans. Using this approach, we validated previously described 25OHD 112 
loci and identified novel genetic determinants of vitamin D. To gain further insight into the genetic 113 
control of the vitamin D metabolic pathway, we looked for overlap of our findings with those of 114 
the an unpublished GWAS on 1,25-dihydroxyvitamin D, the active form of vitamin D, which is 115 
downstream from 25OHD in the vitamin D metabolic pathway (Figure 1). We assessed the 116 
identified lead 25OHD variants for interaction with season of 25OHD measurement. Finally, we 117 
undertook an in silico functional follow-up of our GWAS findings, to identify enrichments in gene 118 
sets, pathways, and expression in tissues, and explore the partitioned heritability of 25OHD and 119 




Material and Methods 122 
Phenotypes 123 
Between 2006 and 2010 approximately half a million British adults were recruited by UK 124 
Biobank47. Participants provided biological samples, physical measurements, and answered 125 
questionnaires relating to general health and lifestyle. Ethical approval was granted by the 126 
Northwest Multi-Centre Research Ethics Committee, and informed consent was obtained from all 127 
participants prior to participation.  128 
 129 
 130 
Data on 25OHD level (in nmol/L) measured using the Diasorin assay were available from 465,415 131 
samples, representing 449,978 UK Biobank participants. Measurements were performed at 132 
baseline (2006-2010), and/or the first follow-up visit (2012-2013). In the present study, we used 133 
baseline 25OHD measurements from 401,460 individuals from the White British subset of UK 134 
Biobank, as defined below. To account for vitamin D supplement use, we adjusted 25OHD levels 135 
by subtracting 21.2 nmol/L from the 25OHD measurement in 24,874 vitamin D supplement users, 136 
representing 6% of our study cohort (see Supplemental Material and Methods for definition of 137 
vitamin D supplementation). We used 21.2 nmol/L because it is the mean increase in 25OHD 138 
levels conferred by taking daily 400IU of cholecalciferol, the amount of vitamin D most often 139 
found in vitamin D supplements48. In 3,057 participants treated with vitamin D supplements, 140 
25OHD levels were lower than 10nmol/L (the detection threshold for Diasorin assay) after 141 
subtraction, and thus they were set to 10nmol/L. 25OHD levels were then log transformed and 142 
standardized to a mean of 0 and standard deviation of 1 (because of skewness in the distribution 143 
of 25OHD levels, and to allow comparison with previous 25OHD GWAS). Distribution of the 144 






After stringent quality control, the UK Biobank genotypes, imputed to the combined Haplotype 149 
Reference Consortium (HRC)49 and UK10K haplotype resource panel, provided 20,370,874 150 
genetic variants from the autosomes and the X chromosome to test for their association with 151 
25OHD levels. This quality control removed low quality genetic variants, by retaining only SNPs 152 
with a minor allele frequency (MAF) > 0.1%, imputation quality score of >0.3 and Hardy–153 
Weinberg P > 1 × 10−6. For details on genotyping and imputation in UK Biobank see the 154 
Supplemental Material and Methods. 155 
 156 
To minimize bias from population stratification, an issue which is particularly relevant in the 157 
search for rare genetic variants associated with traits and disease50, analysis was restricted to 158 
individuals of White British ancestry, which comprises the largest single ancestral group 159 
represented in the UK Biobank.  It is important to distinguish between the self-identified “White 160 
British” in UK Biobank, and the White British subset used in our analysis, where the latter was 161 
defined using a principal component analysis. Specifically, we previously defined this White 162 
British subset using high-quality genotypes, employing FlashPCA 51 and linkage-disequilibrium-163 
pruned HapMap3 SNPs (MAF > 1%, minor allele count > 5, Hardy-Weinberg Equilibrium P > 1x 164 
10-6), which were projected onto previously computed principal components using the same SNPs 165 
set from 1000 Genomes Phase 3 dataset (N=2,504)52. Henceforth, whenever the term “White 166 
British” appears in this paper, it refers to the White British subset defined as above. Details on this 167 
analysis are provided in the Supplemental Material and Methods. Descriptive statistics of this 168 




We then tested the additive allelic effects of SNPs on 25OHD levels, using a linear mixed-model 171 
in the BOLT-LMM software53. The model-fitting was performed on hard-called genotypes from 172 
488,377 participants consisting of 803,113 SNPs. Age, sex, season of 25OHD measurement (as a 173 
categorical variable; 1 for winter [January to March];2 for spring [April to June];3 for summer 174 
[July to September], and 4 for fall [Oct to Dec]), genotype batch, genotype array, and assessment 175 
center (as a proxy for latitude) were included as covariates in the BOLT-LMM. We have 176 
previously estimated that 6.6 × 10−9 is an appropriate p-value threshold for genome wide 177 
significance for analyzing data from the UK Biobank using the above criteria, accounting for 178 
multiple testing52. 179 
 180 
Meta-analysis 181 
We compared the results of the GWAS on UK Biobank to those of a previous 25OHD GWAS 182 
published by our group (n=42,274 samples of European ancestry)12, by performing Pearson 183 
correlation of the betas of all variants with p-values <1 x 10-6 in both GWAS using the ‘cor.test’ 184 
function in R. We then combined the summary level results of the two GWAS in an inverse 185 
variance weighted fixed effects meta-analysis, using the GWAMA54 software. Of note, in both 186 
GWAS, 25OHD levels were first log-transformed and then standardized to a mean of 0 and a 187 
standard deviation of 1. This approach allowed the inverse variance weighted meta-analysis of the 188 
results. 25OHD levels in both GWAS were adjusted for age, sex, genotyping center, and season 189 
of measurement. In the earlier GWAS12, 25OHD levels were adjusted for BMI. Since BMI is a 190 
heritable trait, we elected not to adjust for it in the UK Biobank GWAS, to avoid introducing 191 
collider bias. Also, in the present GWAS on UK Biobank, 25OHD measures were adjusted for 192 
vitamin D supplementation, since this information was available for all participants, contrarily to 193 
 
 10 
the earlier 25OHD GWAS. 194 
 195 
Approximate conditional association analysis 196 
To identify conditionally independent SNPs from this meta-analysis, we used GCTA-COJO 197 
version 1.91.155; 56, which conditions upon the lead SNP per locus by approximating the genotype-198 
phenotype covariance with correlation matrices and summary statistics (Supplemental Material 199 
and Methods). Variants with high collinearity (multiple regression R2 > 0.9) were excluded, and 200 
those situated more than 20,000 pairs away were assumed to be independent. A reference sample 201 
of 50,000 unrelated white British individuals randomly selected from the UK Biobank was created 202 
for a previous GWAS52, and was used to model patterns of linkage disequilibrium (LD) between 203 
variants. We retained as conditionally independent variants those reaching a genome-wide 204 
significant p-value pre- and post-conditioning, and with at least one genome-wide significant 205 
satellite SNP within 250,000 pairs. These variants were then positionally and functionally 206 
annotated to the physically closest gene using the hg19 gene range list, and the Variant Effect 207 
Predictor57 as implemented in PhenoScanner v2.58  208 
 209 
Estimation of variance explained by significant variants and SNP heritability 210 
We estimated the proportion of 25OHD phenotypic variance tagged by all SNPs on the genotyping 211 
array (that is, the SNP heritability) using BOLT-REML function 53 in the UK Biobank GWAS. To 212 
estimate the variance explained by independent genome-wide significant SNPs (that is, all the 213 
genome-wide significant conditionally independent lead SNPs), we summed the variance 214 
explained per independent SNP using the formula: variance explained ≈ 2 2 ƒ(1– ƒ), where  and 215 
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ƒ denote the effect estimate and the effect allele frequency of the allele on a standardized 216 
phenotype, respectively59. 217 
 218 
Interaction analysis with season 219 
25OHD levels are affected by the season of their measurement, which is a proxy for exposure to 220 
UVB. To assess if there is an effect modification of the 25OHD SNPs by season, we undertook an 221 
interaction analysis of our conditionally independent lead SNPs with season of 25OHD assessment 222 
in UK Biobank. First, we visually inspected the mean 25OHD concentrations per season (Figure 223 
S2), and we selected two discrete seasons in order to optimize the comparisons between seasons 224 
with higher and lower mean 25OHD levels (“winter”-individuals assessed Jan-Mar (N=98,674), 225 
and “summer”-individuals assessed Jul-Sep (N=95,135). Individuals with vitamin D levels 226 
assessed in spring (Apr-Jun) and fall (Oct-Dec) were not included in these analyses. Linear 227 
regression was conducted under an additive genetic model. The following variables and co-228 
variables were included in the model: standardized log-transformed serum 25OHD adjusted for 229 
vitamin D supplementation as the dependent variable; SNP genotype (coded as 0, 1 or 2) as an 230 
independent variable; SNP (genotype)* season of 25OHD measurement (coded as a binary 231 
variable: 0 for winter and 1 for summer) as an interaction term; age, sex, season of 25OHD 232 
measurement as covariates. P-values below a Bonferroni-corrected threshold (0.05/number of 233 
COJO-independent SNPs tested for interaction) for the interaction term implied a significant 234 
interaction between season and the tested SNP. 235 
 236 
Assessment of inflationary bias in GWAS results 237 
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By estimating the lambda GC and the LD score regression (LDSR) intercept, BOLT-LMM 238 
software estimated the amount of genomic inflation present in the data that was due to residual 239 
population stratification, cryptic relatedness, and other latent sources of bias in the UK Biobank 240 
GWAS. We used the lambda GC from GWAMA to estimate the genomic inflation in the meta-241 
analysis of the UK Biobank GWAS and compared this with the previous GWAS meta-analysis12.  242 
 243 
In-silico functional follow-up 244 
Functional follow-up of the meta-analysis summary statistics was performed using Complex Trait 245 
Genomic-Virtual Lab60 web application, which implements a variety of follow-up methods for 246 
GWAS summary statistics output from the COJO analysis  (Supplemental Material and 247 
Methods). In brief, association between predicted gene transcription and 25OHD was estimated 248 
using S-MultiXcan61 in the MetaXcan package with the default options implemented. Association 249 
statistics for the 48 tissues were combined accounting for correlation between tissues to give 250 
transcript-level results, and a Bonferroni correction was applied to account for the number of gene 251 
transcripts tested. Gene prioritisation, gene set and tissue enrichment analysis were performed 252 
using DEPICT (Data-driven Expression-Prioritized Integration for Complex Traits)62; 63  to 253 
identify likely causal genes at associated loci, highlight gene pathways which are over-represented 254 
by associated loci in the single variant results and test whether expression of these genes is enriched 255 
in specific tissue types. Genetic correlation between 25OHD and a range of other traits available 256 
as publicly available GWAS summary statistics was examined using bivariate LDSR64 257 
implemented in the LD Hub platform65.  Finally, partitioned heritability by functional annotation 258 
with 53 overlapping categories was performed using stratified LDSR using the baseline model 259 
from 1000 Genomes phase 3 data (baselineLD_v2.2, February 2019)64; 66. Cell specific heritability 260 
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was examined using the --h2-cts flag in LDSR and the multi-tissue gene expression file 261 
("Multi_tissue_gene_expr" containing both GTEx data and Franke lab dataset of microarray gene 262 
expression)65. These final two analyses were restricted to common variants present in HapMap3 263 
(approximately 1,500,000 SNPs), excluding those within the HLA region defined as Chr6: 264 
25000000 to 34000000 bases inclusive. 265 
 266 
GWAS on 1,25-dihydroxyvitamin D 267 
Study participants, genotyping and imputation 268 
The Ely Study, established in 1990, is a prospective study of the aetiology of type 2 diabetes and 269 
has been described in detail elsewhere. We studied Ely participants with measures of 1,25- 270 
dihydroxyvitamin D to estimate genetic effects the active form of vitamin D67; 68. Briefly, Ely 271 
comprises individuals of European ancestry aged 40-69 years, registered at a single medical 272 
practice in Ely, Cambridgeshire, UK and evaluated in 3 phases. All participants of the Ely Study 273 
gave their written informed consent and the study was approved by the local ethics committee. 274 
Participants at Phase 3 were genotyped using the HumanCoreExome-24 and InfiniumCoreExome 275 
arrays. Details of the genotype quality control appear in Supplemental Material and Methods. 276 
A total of 1,591 samples and 546,486 variants met the quality control criteria. Imputation was 277 
performed using the Sanger Imputation Server (pre-phase with EAGLE2 and impute with PBWT 278 
pipeline), and the HRC 1.1 reference panel49. Additional variants not captured by the HRC 279 
reference panel were imputed using a combined UK10K and 1000 Genomes Phase 3 reference 280 




1,25-dihydroxyvitamin D phenotype and look-up for the 25OHD conditionally independent 283 
SNPs 284 
Phase 1 1,25-dihydroxyvitamin D levels and genetic data were available for 748 Ely participants. 285 
Levels of 1,25-dihydroxyvitamin D were natural log transformed before regressing with the 286 
inclusion of age, sex, body mass index and season as covariates. Residuals from the regression 287 
were standardised and used as the final 1,25-dihydroxyvitamin D phenotype. Genetic association 288 
analysis was performed for the conditionally independent variants from the 25OHD GWAS meta-289 
analysis using SNPTEST v2.5.4-beta369. Bonferroni adjustment was applied to association test p-290 
values such that variants with GWAS p-values <4.10x10-4 (0.05/122) were considered to meet the 291 
corrected significance threshold.  292 
 293 
Results 294 
GWAS for 25OHD levels 295 
The GWAS in UK Biobank included 401,460 participants and 20,370,874 variants. The genomic 296 
control lambda in BOLT-LMM was 1.23, and the LDSR intercept was 1.06 (Figure S3). We found 297 
a strong correlation between the effect sizes of the UK Biobank GWAS with our previous GWAS 298 
meta-analysis12. Specifically, we compared the betas of 20,787 SNPs achieving p-values < 1 x10-299 
6 in both GWAS (minimum MAF 0.3%) and found a coefficient of correlation (r) of 0.88 (Figure 300 
S4). We then performed a meta-analysis of the two GWAS on a total of 16,668,957 SNPs (Figure 301 
2). The lambda GC of the meta-analysis was 1.23. Using approximate conditional analysis as 302 
implemented by GCTA–COJO, we observed 138 conditionally independent signals (pre- and post- 303 
conditioning p-value< 6.6 x10-9), mapping to 69 loci (a locus was defined as 1 Mb region around 304 
the SNP reaching the lowest p-value), 63 of which were not reported in previous 25OHD GWAS 305 
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(Table 1 and Table S2). Of these conditionally independent SNPs, 53 (38%) had MAF<5%, and 306 
85 (62%) were common (MAF5%). The 53 SNPs with MAF <5% conferred an average absolute 307 
effect of 0.23 standard deviations on standardized log transformed 25OHD levels per effect allele, 308 
compared to 0.03 standard deviations of the 85 SNPs with MAF5% (Figure S5). 309 
 310 
The total variance explained by the 138 conditionally independent genome-wide significant 311 
vitamin D SNPs was 4.9%. When partitioning the variance explained by these lead SNPs into two 312 
MAF categories, we found that low-frequency and rare variants explained 1.8% of the variance in 313 
25OHD levels, whereas common variants explained 3.1% of the variance, respectively.  The SNP 314 
heritability from all SNPs, independent of GWAS p-value, as estimated by BOLT-LMM on 315 
805,426 hard called variants in UK Biobank was 16.1%, indicating that genome-wide significant 316 
independent variants capture less than a third of the variance explained in 25OHD levels by all 317 
directly genotyped markers.  318 
 319 
Look-up of the 25OHD GWAS variants in the 1,25-dihydroxyvitamin D GWAS 320 
We tested 122 out of the 138 conditionally independent variants from the 25OHD GWAS for 321 
genetic association with 1,25-dihydroxyvitamin D. The 16 variants that were not tested were not 322 
available in the Ely dataset, either because they were not reliably captured through imputation, or 323 
had low MAF (<0.001), and no suitable proxy variant could be identified.  Among the 122 324 
conditionally independent variants tested in Ely for association with 1,25-dihydroxyvitamin D, 325 
only one rs6127099 in the CYP24A1 locus on chromosome 20 reached the multiple testing 326 
corrected threshold for significance (20:52731402:T_A; β=0.231; p=2.5 x 10-4 )(Table 1 and 327 
 
 16 
Table S2). Finally, among the 122 SNPs, 74 SNPs had a consistent direction of effect on 25OHD 328 
and on 1,25-dihydroxyvitamin D levels.  329 
 330 
Interaction analysis with season 331 
To investigate the hypothesis that the effect of some of the 25OHD variants is modified by 332 
season of measurement, we tested the presence of interaction of the 138 conditionally 333 
independent variants with season in 193,809 White British participants, whose 25OHD levels 334 
were assessed in summer or in winter. We found significant interaction with season in 11 335 
independent SNPs in the CYP2R1 locus on chromosome 11, and in a single variant in the 336 
SEC23A locus on chromosome 14 (all p-values below the Bonferroni-corrected threshold of 3.6 337 
x 10-4) (Table 1 and Table S2). The strongest interaction was found for rs117913124 (p-value 338 
for interaction 1.5 x 10-55), a previously described low frequency variant in CYP2R1 with large 339 
effect on 25OHD levels (absolute GWAS beta per allele of 0.35 units in standardized log-340 
transformed 25OHD).  For all 12 SNPs achieving significant interaction p-values, the direction 341 
of the beta for the interaction term genotype*season summer was in the same direction as the 342 
direction of the beta on 25OHD levels, meaning that the vitamin D lowering effect of these SNPs 343 
“blunts” the expected increase in 25OHD in summer. 344 
 345 
In silico functional follow-up 346 
Gene prioritisation and enrichment analyses 347 
Gene prioritisation analysis suggested 70 genes with FDR<5% which might plausibly underlie the 348 
distribution of association statistics seen in the single variant results.  At many loci, genes within 349 
the vitamin D metabolism pathway were suggested as plausible candidates. For example, DEPICT 350 
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prioritized DHCR7 at the lead associated chr11:70313961-71239227 locus and GC at 351 
chr4:72607410-72669758 locus. Interestingly, ADH6 [MIM:103735] was a plausible candidate at 352 
locus chr4:99916771-100274184 suggesting this locus may have pleiotropic effects on vitamin D 353 
and alcohol metabolism (Table S3). 354 
 355 
Gene set enrichment analysis identified enrichment in 418 pre-defined gene sets with a false 356 
discovery rate (FDR) < 5%. The strongest statistical evidence for enrichment was in the following 357 
gene sets: the alpha-2-HS Glycoprotein (AHSG), a negatively-charged serum glycoprotein that is 358 
synthesized by hepatocytes involved in several processes, including endocytosis, brain 359 
development, and the formation of bone tissue (p=4.18x10-7); the reactome gene set for 360 
“metabolism of lipids and lipoprotein” (p=7.91x10-7); several genes involved in immune pathways 361 
and therefore expressed in the blood such as ‘Elastase, Neutrophil Expressed (ELANE)’ 362 
(p=8.43x10-7); the ‘Serum albumin (ALB)’ (p=1.19x10-6), ‘Acidic form of complement factor 4 363 
(C4A)’ (p=1.51x10-6) and ‘ENSG00000211949’ gene sets, belonging to the immunoglobulin (Ig) 364 
heavy chain locus (p=1.51x10-6); biosynethic pathways such as “GO:0044283, small molecule 365 
biosynthetic process, p=1.89x10-6”, “GO:0016053, organic acid biosynthetic process, p=2.29x10-366 
6; GO:0046394” and “carboxylic acid biosynthetic process, p=2.29x10-6”;  and finally liver 367 
associated pathways including  “MP:0000599, enlarged liver, p=1.33x10-6”, “GO:0001889, liver 368 
development, p=3.35x x10-6” and “GO:0061008, hepaticobiliary system development, p=4.15x10-369 
6” (Table S4).  Finally, expression of 25OHD genes was enriched in 17 cell types with an FDR < 370 
5%, including cell lines representing the liver (hepatocytes, p=1.63x10-6) and skin (keratinocytes, 371 
p=7.73x10-3). The tissue-specific analysis found greatest evidence for enrichment in the liver 372 
(p=1.34x10-6) and the gastrointestinal tract (p=2.22x10-3) (Table S5), which is in accordance with 373 
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the fact that 25OHD is hydroxylated in the liver70, but also conjugates with glucuronide71 and 374 
sulfate72 to get excreted in the bile and then gets reabsorbed by the enterohepatic circulation. 375 
Collectively, these findings suggest that detectable serum 25OHD levels are influenced by a range 376 
of metabolic processes within known physiological pathways, but also extending beyond the 377 
canonical vitamin D metabolic pathway.  378 
 379 
Predicted gene transcription levels 380 
After applying a Bonferroni-corrected multiple testing threshold (p<1.94x10-6), varying 381 
expression levels at 377 gene transcripts were predicted to influence 25OHD, out of a total of 382 
25,816 that were tested. Results for all gene transcripts are shown in Figure 3. This indicates that 383 
although there are 69 loci associated with vitamin D phenotype, there are potentially 377 gene 384 
transcripts across multiple tissues whose expression may influence vitamin D. The lead associated 385 
genetic transcripts using S-MulTiXcan61 were consistent with the lead association signals in the 386 
single variant results, for example identifying association at NADSYN1 [MIM:608285](Z-test 387 
p<1.81x10-309); DHCR7 (Z-test p<1.15x10-245); GC (Z-test p<1.81x10-309); CYP2R1 (Z-test 388 
p=2.85x10-277); UGT1A4 [MIM:606429] (Z-test p=3.25x10-34); PADI1 [MIM: 607934] (Z-test 389 
p=3.64x10-23). The S-MulTiXcan61 method integrates information from multiple tissue-specific 390 
predictions improving the statistical power over the single variant method and highlights additional 391 
transcripts associated with 25OHD, with the strongest evidence in various forms of Keratin 392 
Associated Protein 5 (KRTAP5 [MIM:608822]) (Z-test p<1.81x10-309), a protein coding gene 393 
involved in keratinization and has been identified as a potential read through for NADSYN1. This 394 
adds further evidence that 25OHD is affected through processes beyond the established vitamin D 395 




Genetic correlation  398 
 Genetic correlation results for 25OHD were available for 774 traits from the LD hub catalogue65, 399 
including 517 raw traits from UK Biobank and 257 from other GWAS studies and consortia 400 
(Figure 4). A total of 101 traits passed a multiple testing corrected Bonferroni p-value threshold 401 
of p<6.46x10-5. The strongest evidence of negative genetic correlation with 25OHD were ‘Time 402 
spent using a computer’ (rg=-0.22) and ‘Qualifications: College or University degree’ (rg=-0.17); 403 
‘Intelligence’ (rg=-0.24). Traits pertaining to exercise (‘Duration of vigorous activity’ (rg=0.22) 404 
and ‘Number of days/week walked 10+ minutes’ (rg=0.18)) had positive genetic correlations with 405 
vitamin D. Traits related to body mass index (BMI) including lipids and diabetes, had a negative 406 
correlation: ‘BMI’ (rg=-0.14); ‘Triglycerides’ (rg=-0.25); ‘Type 2 Diabetes’ (rg=-0.19). A full list 407 
of results can be found in Table S7.   408 
 409 
 410 
Tests for enrichment in functional annotations 411 
Using information from all the SNPs in the 25OHD GWAS summary statistics and modelling LD 412 
with the 53 functional categories not specific to any cell type in the baseline model, there was 413 
evidence for enrichment in 3 out of the 95 functional annotations tested. These were annotations 414 
providing evidence for evolutionary conservation with 2% of variants annotated as highly 415 
conserved accounting for 20% of the heritability of vitamin D (9-fold enrichment over baseline, 416 
p=1.48x10-5) (Table S8). There was little evidence from stratified LDSR66 that vitamin D 417 
heritability is enriched in gene sets expressed specifically in given cells or tissue types. However, 418 
it is worth noting that the highest LDSR coefficients were seen for genomic regions specifically 419 
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expressed in hepatocytes (coefficient = 1.17x10-8), liver (coefficient = 1.73 x10-8) and whole blood 420 




This large-scale GWAS meta-analysis identified 63 novel genetic loci which were associated with 425 
25OHD levels in people of European ancestry and at least doubled the estimate of SNP heritability 426 
of 25OHD levels. Our study also replicated the 6 known vitamin D loci (in or near CYP2R1, 427 
DHCR7, GC, CYP24A1, AMDHD1, SEC23A). In silico follow-up identified enrichment in gene 428 
sets and pathways mostly independent from canonical vitamin D synthesis and metabolism 429 
pathways. Taken together, these results identify new biological pathways that influence 25OHD 430 
levels and demonstrate that this metabolite is moderately polygenic.  431 
 432 
The large number of low-frequency and rare variants of large effect among the 138 conditionally 433 
independent variants of our GWAS is remarkable and suggests that 25OHD levels have a 434 
somewhat distinct genetic architecture when compared to other common traits. Specifically, the 435 
average absolute effect on 25OHD of the 53 low-frequency and rare variants was at least 7 times 436 
larger than the average effect of the 85 common SNPs, but their contribution to the explained 437 
variance of 25OHD was smaller than that of the common SNPs (1.8% vs 3.1%). This is not 438 
surprising, given the limited frequency of these variants in the general European population. 439 
GWAS with larger sample sizes are needed to further dissect the contribution of rare variants with 440 




The hypothesis-free approach of GWAS has served to highlight the role of lipid biology in 25OHD 443 
levels—a fat-soluble hormone. Specifically, among the 69 identified 25OHD loci, 22 loci are 444 
related to serum lipid phenotypes. Examples of these loci are the lipase C (LIPC [MIM:151670]) 445 
on chromosome 15, the low density lipoprotein receptor (LDLR [MIM:606945]) and the 446 
apolipoprotein C1 (APOC1 [MIM107710]) on chromosome 19, and the cholesteryl ester transfer 447 
protein (CETP [MIM:118470]) on chromosome 16. Additionally, our gene enrichment analysis 448 
prioritized the metabolism of lipids and lipoprotein gene set, and lipid traits were strongly 449 
genetically correlated with 25OHD using LDSR. These findings suggest that 25OHD levels share 450 
several of the same biological pathways influencing circulating lipids.  451 
 452 
We also found enrichment in loci harboring genes associated with skin keratinization. Among 453 
these, an interesting finding was the FLG [MIM:135940] on the chromosome 1, which encodes 454 
fillagrin, a protein which plays an important role in the skin barrier’s function, and deregulation of 455 
this function might affect vitamin D in the skin, which is also synthetized in the skin. Another 456 
locus related to skin keratinization was the KRTAP5, which was prioritized by our in silico 457 
analyses. However, functional follow-up of these novel loci is required, to characterize the causal 458 
genes and/or mechanisms underlying the associations with 25OHD levels. Also, we observed 459 
enrichment in loci associated with traits outside the vitamin D pathway, which are not directly 460 
linked to 25OHD synthesis and metabolism. We can speculate on the exact mechanism of action 461 
of these genes on 25OHD—for instance through their effect on time spend outdoors and 462 
consequently exposure to sunlight—but follow-up experiments are necessary to validate these 463 




The results of the interaction analysis with season merit some discussion too. We found evidence 466 
for significant interaction with multiple independent common, low-frequency and rare SNPs in 467 
the CYP2R1 locus. CYP2R1 encodes the enzyme responsible for 25-hydroxylation of vitamin D 468 
in the liver 70, a necessary step in the conversion of vitamin D synthetized in the skin after 469 
exposure to UVB to 25OHD. Therefore, it is not surprising that individuals heterozygous or 470 
homozygous for variants in or near CYP2R1 show a smaller change in their 25OHD levels as a 471 
response to season compared to non-carriers. In other words, we observed that carriers of the 472 
effect alleles in this locus have steadily lower 25OHD levels, independently of the season of their 473 
measurement. We also observed significant interaction with a common SNP in the SEC23A 474 
gene, which is involved in endoplasmic reticulum (ER)-Golgi protein trafficking. Although the 475 
exact mechanism with which SEC23A interacts with season to regulate 25OHD levels remains 476 
unknown, it might act as a regulator of the enzymatic activity of CYP2R1, which is located in 477 
the endoplasmic reticulum. Functional follow-up experiments are warranted to investigate this 478 
hypothesis. 479 
 480 
The findings of the look-up of the significant 25OHD SNPs in the 1,25-dihyxroxyvitamin D 481 
GWAS provide evidence that the two biomarkers of vitamin D in humans have, to a certain extent, 482 
a shared genetic component. This may be expected as both biomarkers share at least the same 483 
vitamin D catabolic pathway. However, the small sample size of the 1,25-dihydroxyvitamin D 484 
GWAS, the only available GWAS on this trait to date, limits the power for characterization of 485 
1,25-dyhydroxyvitamin D loci. We can therefore speculate that there might be a larger overlap of 486 
the genetic architecture of the two biomarkers. 1,25-dihydroxyvitamin D is the active metabolite 487 
of vitamin D, and although its levels directly regulate the effects of vitamin D on a cellular level, 488 
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it remains understudied because of its short half-life, low concentration in blood73 and the body’s 489 
ability to buffer 1,25-dihydroxyvitamin D in deficient individuals by increasing parathyroid 490 
hormone. In that aspect, any additional evidence, from larger 1,25-dihydroxyvitamin D GWAS, 491 
linking 25OHD levels to those of 1,25-dihydroxyvitamin D in the genetic level will be important, 492 
as it will add to our understanding of the vitamin D physiology. 493 
 494 
Collectively the results of our analyses suggest that serum levels of 25OHD are in crosstalk with 495 
a range of metabolic processes extending within the canonical vitamin D metabolic pathway (skin 496 
synthesis, hepatic hydroxylation, sulfonylation, glucuronylation), and beyond (time of computer 497 
use, intelligence, educational achievement). Although not specifically tested in the present study, 498 
one implication of these findings is that the potential genetic instruments for vitamin D are 499 
instrumenting more than the vitamin D pathway, and specifically they also capture variance in 500 
traits that relate to environmental confounders that could influence 25OHD levels. Taken together, 501 
our findings present a cautionary tale for future MR studies using 25OHD as an exposure, based 502 
on this GWAS, since there is a risk of pleiotropic effects for a substantial number of novel 25OHD-503 
related SNPs mapping to genes not directly involved in 25OHD biology.  504 
 505 
In summary, we described 63 novel loci which are associated with 25OHD levels in Europeans. 506 
Further research is warranted to better characterize the novel genetic variants, replicate these 507 
findings in independent European samples, validate them in other ethnic groups and identify 508 
ancestry-specific variants, and to better understand the biological pathways influencing 25OHD 509 
levels.  The genetic instruments for 25OHD identified here should be used with caution in future 510 
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Figure 1. The vitamin D metabolic pathway 770 
Figure 2. Genome-wide association of 25OHD graphed by chromosome positions and 771 
−log10 P-value (Manhattan plot), and quantile-quantile plot of the GWAS meta-analysis 772 
(QQ-plot) on 443,374 European individuals. A Manhattan plot: The P-values were obtained 773 
from the fixed-effects inverse variance weighted meta-analysis. Horizontal red dash line 774 
represents the thresholds of P = 6.6×10−9 for genome-wide significance. Known loci were 775 
colored coded as blue diamonds, novel rare loci were color coded as red diamonds, and novel 776 
common loci were color coded as white diamonds. B QQ-plot: The Y axis (observed −log10 P-777 
values) is truncated at 310; the X axis shows the expected −log10 P-values. Each SNP is plotted 778 
as a blue dot, and the dash red line indicates null hypothesis of no true association. Deviation 779 
from the expected P-value distribution is evident only in the tail area, with a lambda of 1.23.  780 
Figure 3. Effect of predicted increased transcription of all genes on circulating vitamin D. 781 
Each dot represents the effect of increased transcription (averaged across all tissue-specific 782 
predictions using S-MultiXcan) on 25OHD.  783 
Figure 4. Genetic correlation between 25OHD levels and GWAS traits available within LD 784 
hub. Each dot represented the Rg between 25OHD and an individual trait. The red dashed line 785 
represents the Bonferroni-corrected multiple testing threshold at the 5% level.  786 
  787 
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Table 1. Association results for 138 conditionally independent SNPs that reach genome-wide significance in the GWAS meta-788 
analysis for 25OHD, and the 1,25 dihydroxyvitamin D GWAS.  789 
CONDITIONALLY INDEPENDENT 25OHD 
ASSOCIATED VARIANTS META-ANALYSIS (N=443,734) GCTA-COJO 
Ely 1,25-dihydroxyvitamin D 
GWAS (N=748) GxE with season LOCUS ANNOTATION 
RSID CHR BP EA EAF MAF β P β.J P.J VAR.J EAF β P 
β 
genotype*season 
Summer P A.GENE FUNCTION 
rs6698680 1 2329661 G 0.46 0.46 -0.01 8.99E-10 -0.01 7.47E-10 0.0001 0.46 -0.06 0.27 -0.018 0.0024 RER1 intron 
rs3750296 1 17559656 C 0.34 0.34 -0.02 2.09E-24 -0.02 3.04E-24 0.0002 0.34 0.00 0.94 -0.004 0.5694 PADI1 intron 
rs7519574 1 34726552 A 0.18 0.18 0.02 2.09E-11 0.02 4.03E-11 0.0001 0.17 -0.08 0.28 -0.013 0.0958 
RP4-
657M3.2 intergenic 
rs56044892 1 41830086 T 0.21 0.21 0.02 2.85E-10 0.02 3.13E-10 0.0001 0.21 -0.01 0.92 0.004 0.5716 FOXO6 intron 
rs2934744 1 63048045 A 0.64 0.36 -0.02 3.96E-26 -0.02 4.13E-26 0.0002 0.63 -0.11 0.04 0.000 0.9646 DOCK7 intron 
rs7528419 1 109817192 G 0.22 0.22 0.02 2.41E-16 0.02 2.43E-16 0.0001 0.23 -0.16 0.01 -0.014 0.0461 CELSR2 3_prime_UTR 
rs3768013 1 150815411 A 0.37 0.37 -0.01 1.37E-13 -0.01 3.86E-09 0.0001 0.38 -0.06 0.30 0.008 0.2182 ARNT intron 
rs115045402 1 152029548 A 0.03 0.03 0.11 3.05E-55 0.07 1.58E-19 0.0003 0.02 0.20 0.36 -0.006 0.8271 FLG intergenic 
rs12123821 1 152179152 T 0.05 0.05 0.07 2.25E-59 0.05 1.28E-24 0.0003 0.04 0.04 0.78 -0.029 0.0391 FLG intron 
rs201561609 1 152187902 T 0.99 0.01 -0.13 6.99E-28 -0.10 6.63E-16 0.0002 0.98 0.02 0.93 -0.027 0.5813 FLG missence 
rs185433896 1 152249021 A 0.99 0.01 -0.25 1.50E-38 -0.21 7.24E-28 0.0006 1.00 -0.24 0.69 -0.128 0.2258 FLG intron 
rs189918701 1 152254152 G 1.00 0.00 -0.24 2.47E-16 -0.18 3.29E-10 0.0002 Not available in Ely datasets  -0.077 0.4942 FLG intron 
rs375984409 1 152255772 G 0.99 0.01 -0.23 3.22E-38 -0.19 1.53E-25 0.0006 Not available in Ely datasets  0.055 0.4834 FLG intron 
rs144613541 1 152270875 G 0.29 0.29 0.02 6.49E-12 0.02 1.52E-12 0.0001 0.28 0.12 0.05 0.008 0.2585 FLG downstream 
rs150597413 1 152277622 T 0.00 0.00 0.10 6.18E-11 0.11 1.56E-12 0.0001 0.00 0.13 0.82 0.034 0.4693 FLG   
rs138726443 1 152280023 A 0.00 0.00 0.11 8.81E-15 0.12 1.36E-17 0.0001 0.01 0.48 0.25 -0.084 0.0557 FLG   
rs61816761 1 152285861 A 0.02 0.02 0.13 8.57E-74 0.11 5.39E-54 0.0005 0.02 -0.01 0.96 -0.021 0.3844 FLG stop_lost 
rs576242124 1 152390763 A 0.01 0.01 0.11 3.08E-15 0.09 2.59E-10 0.0002 0.01 0.29 0.42 -0.061 0.2780 FLG upstream 
rs184958517 1 153111312 T 0.99 0.01 -0.13 5.55E-15 -0.11 1.21E-09 0.0002 1.00 0.17 0.79 0.017 0.8560 FLG downstream 
rs558560635 1 153147997 G 1.00 0.00 -0.27 5.83E-16 -0.24 4.45E-13 0.0003 Not available in Ely datasets  -0.001 0.9953 FLG intron 
rs11264360 1 155284586 A 0.24 0.24 0.02 3.34E-15 0.02 1.12E-15 0.0001 0.23 -0.09 0.16 -0.011 0.1237 FDPS indels 
rs867772 1 220972343 G 0.68 0.32 -0.01 3.64E-11 -0.01 3.31E-11 0.0001 0.69 0.00 0.97 0.001 0.8839 MARC_1 intron 
rs10127775 1 230295789 T 0.60 0.40 0.01 3.43E-09 0.01 3.11E-09 0.0001 0.60 0.01 0.87 0.016 0.0074     
rs12997242 2 21381177 A 0.44 0.44 -0.01 2.23E-10 -0.01 2.32E-10 0.0001 0.43 -0.01 0.89 -0.008 0.1958 TDRD15 intergenic 
rs11127048 2 27752463 A 0.62 0.38 0.02 6.41E-19 0.02 6.72E-19 0.0002 0.63 0.03 0.63 0.004 0.4918 GCKR intergenic 
rs6724965 2 101440151 G 0.17 0.17 -0.02 1.29E-10 -0.02 1.34E-10 0.0001 0.18 0.07 0.31 -0.001 0.9476 NPAS2 intron 
rs7569755 2 118648261 A 0.29 0.29 0.01 8.03E-11 0.01 8.35E-11 0.0001 0.28 -0.03 0.64 0.000 0.9838 HTR5BP intron 
rs1047891 2 211540507 A 0.32 0.32 -0.01 1.16E-11 -0.01 1.16E-11 0.0001 0.32 -0.01 0.81 -0.004 0.4934 CPS1 missence 
rs2011425 2 234627608 G 0.08 0.08 -0.05 9.66E-38 -0.05 9.93E-38 0.0003 0.06 0.08 0.45 -0.002 0.8714 UGT1A4 missence 
rs7650253 3 49431160 A 0.69 0.31 0.01 1.76E-10 0.01 1.76E-10 0.0001 0.69 0.00 0.99 -0.017 0.0126 RHOA intron 
rs1972994 3 85631142 T 0.65 0.35 -0.02 7.99E-18 -0.02 8.04E-18 0.0001 0.67 -0.11 0.05 -0.005 0.4647 CADM2 intron 
rs6438900 3 125148287 G 0.26 0.26 0.01 9.59E-10 0.01 1.16E-09 0.0001 0.25 -0.01 0.93 -0.014 0.0391 MRPL3 intergenic 
rs6773343 3 141825598 T 0.72 0.28 0.01 5.20E-09 0.01 6.28E-09 0.0001 0.72 0.02 0.76 0.001 0.8707 TFDP2 intron 
rs78649910 4 3482213 A 0.11 0.11 -0.02 4.32E-09 -0.02 3.41E-09 0.0001 0.12 -0.02 0.79 0.007 0.4484 DOK7 intron 
rs7699711 4 69947596 T 0.45 0.45 -0.03 6.97E-49 -0.03 4.85E-50 0.0004 0.43 0.01 0.88 0.000 0.9588 UGT2B7 intron 
rs529640451 4 72177044 C 1.00 0.00 0.23 2.25E-17 0.17 2.20E-10 0.0002 Not available in Ely datasets  -0.165 0.1887 GC intergenic 
rs528776789 4 72486140 A 0.99 0.01 0.18 3.67E-31 0.12 2.45E-15 0.0002 0.99 0.06 0.90 0.053 0.4581 GC intergenic 
rs113938679 4 72488025 A 0.01 0.01 -0.18 5.88E-36 -0.10 2.21E-11 0.0001 0.01 0.20 0.65 0.042 0.4317 GC intergenic 
rs564377207 4 72488525 G 1.00 0.00 -0.20 1.05E-21 -0.16 2.23E-14 0.0002 1.00 -0.64 0.22 -0.013 0.9058 GC intergenic 
rs186897112 4 72528565 G 1.00 0.00 0.25 3.79E-13 0.20 3.81E-09 0.0002 Not available in Ely datasets  -0.147 0.3323 GC intergenic 
rs557657187 4 72539857 G 1.00 0.00 0.37 6.18E-16 0.29 2.19E-10 0.0002 Not available in Ely datasets  -0.274 0.0977 GC intergenic 
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rs145432346 4 72575017 C 0.83 0.17 0.11 6.78E-286 0.03 2.26E-27 0.0003 0.82 0.20 0.01 0.004 0.7215 GC intergenic 
rs705117 4 72608115 T 0.85 0.15 -0.03 1.71E-36 0.03 1.12E-27 0.0003 0.87 0.06 0.47 0.002 0.7808 GC intron 
rs11723621 4 72615362 G 0.29 0.29 -0.19 2.903E-1689 -0.16 0 0.0101 0.29 -0.08 0.19 0.011 0.0871 GC intron 
rs560384646 4 72616618 C 0.02 0.02 -0.19 6.91E-112 -0.09 3.23E-24 0.0004 0.02 -0.54 0.07 0.022 0.4814 GC indel 
rs200641845 4 72620895 T 0.55 0.45 0.02 6.92E-14 0.02 5.23E-12 0.0001 0.56 -0.16 0.02 -0.022 0.0113 GC intron 
rs565277381 4 72625772 T 1.00 0.00 0.31 6.62E-11 0.28 3.55E-09 0.0002 Not available in Ely datasets  -0.144 0.4506 GC intron 
rs3775150 4 72640750 C 0.26 0.26 -0.09 3.90E-295 -0.07 3.46E-109 0.0019 0.27 0.03 0.68 -0.002 0.7781 GC indel 
rs222026 4 72643760 T 0.87 0.13 -0.05 6.98E-68 -0.05 1.09E-40 0.0006 0.86 -0.05 0.50 0.012 0.2171 GC intron 
rs190688847 4 72705716 C 1.00 0.00 0.29 1.02E-18 0.25 1.26E-14 0.0003 Not available in Ely datasets  0.002 0.9879 GC intergenic 
rs184291421 4 72752846 C 0.99 0.01 0.17 1.25E-28 0.09 5.03E-09 0.0001 1.00 -0.38 0.39 -0.064 0.2998 GC intergenic 
rs188838036 4 72783385 A 1.00 0.00 0.18 3.07E-24 0.12 3.14E-11 0.0001 0.99 0.54 0.20 0.007 0.9173 GC intergenic 
rs186881826 4 72785743 A 0.22 0.22 0.05 3.64E-77 0.02 1.43E-15 0.0001 0.23 -0.05 0.44 0.000 0.9645 GC intergenic 
rs186441690 4 72820969 G 1.00 0.00 -0.27 1.96E-18 -0.23 1.79E-14 0.0003 Not available in Ely datasets  0.280 0.0786 GC intergenic 
rs546541682 4 72864566 T 0.99 0.01 -0.16 2.06E-18 -0.11 3.45E-10 0.0001 0.99 0.37 0.46 0.059 0.5093 GC intergenic 
rs143106299 4 72920085 T 0.01 0.01 -0.17 1.50E-28 -0.09 4.62E-09 0.0001 0.00 -0.02 0.97 0.126 0.0913 GC intron 
rs192785674 4 73505826 A 1.00 0.00 0.17 8.14E-11 0.18 3.48E-12 0.0002 Not available in Ely datasets  -0.116 0.4965 GC intergenic 
rs58073039 4 88287363 G 0.30 0.30 -0.01 2.16E-11 -0.01 2.84E-10 0.0001 0.28 -0.04 0.45 0.015 0.0224 HSD17B11 intron 
rs28364331 4 100201295 G 0.02 0.02 0.06 1.31E-17 0.06 3.06E-18 0.0001 0.02 0.08 0.70 0.050 0.0227 ADH1A splice_region 
rs1229984 4 100239319 C 0.97 0.03 -0.05 4.85E-13 -0.05 2.43E-13 0.0001 0.97 -0.04 0.84 0.014 0.4919 ADH1A missence 
rs7718395 5 118652574 G 0.32 0.32 0.01 1.67E-09 0.01 1.68E-09 0.0001 0.31 0.04 0.52 0.006 0.3912 TNFAIP8 intron 
rs3822868 6 131934986 G 0.84 0.16 0.02 1.41E-15 0.02 1.41E-15 0.0001 0.84 0.15 0.02 -0.010 0.2213 MED23 intron 
rs111529171 7 21571932 C 0.22 0.22 -0.02 6.24E-11 -0.02 6.26E-11 0.0001 0.22 0.04 0.50 0.000 0.9982 DNAH11 intergenic 
rs1011468 7 104613791 A 0.48 0.48 -0.01 1.35E-12 -0.01 1.39E-12 0.0001 0.44 -0.12 0.02 0.013 0.0327 LINC01004 intron 
rs1858889 7 107117447 C 0.50 0.50 0.01 3.85E-11 0.01 3.03E-11 0.0001 0.50 -0.02 0.66 -0.010 0.1046 COG5 intron 
rs804280 8 11612698 A 0.58 0.42 0.01 4.43E-11 0.02 9.90E-16 0.0001 0.57 -0.06 0.22 -0.014 0.0207 GATA4 intron 
rs34726834 8 25889606 T 0.25 0.25 0.01 6.65E-10 0.01 3.39E-10 0.0001 0.27 -0.04 0.48 -0.010 0.1456 EBF2 intron 
rs7828742 8 116960729 G 0.60 0.40 -0.02 3.06E-28 -0.02 2.85E-33 0.0003 0.60 -0.03 0.51 0.000 0.9401 LINC00536 downstream 
rs10818769 9 125719923 G 0.86 0.14 -0.02 3.35E-09 -0.02 2.99E-09 0.0001 0.84 0.04 0.59 -0.001 0.9333 DNAH11 intergenic 
rs532436 9 136149830 A 0.18 0.18 -0.02 2.17E-09 -0.02 1.94E-09 0.0001 0.21 0.04 0.55 -0.014 0.0590 ABO intron 
rs10887718 10 82042624 T 0.53 0.47 -0.01 1.44E-10 -0.01 1.18E-10 0.0001 0.51 0.03 0.54 -0.001 0.8903 MAT1A intron 
rs538325438 11 13414030 C 1.00 0.00 0.23 6.07E-13 -0.45 4.61E-32 0.0006 Not available in Ely datasets  0.111 0.2836 CYP2R1 intron 
rs373514022 11 13955649 C 1.00 0.00 0.20 4.77E-12 0.21 4.15E-13 0.0002 1.00 -0.89 0.19 -0.067 0.5386 CYP2R1 intergenic 
rs571618690 11 13996822 A 1.00 0.00 0.37 1.90E-31 0.23 1.40E-12 0.0001 Not available in Ely datasets  0.517 2.7E-06 CYP2R1 intron 
rs191379475 11 14075712 G 0.99 0.01 -0.10 1.70E-15 -0.09 1.22E-11 0.0002 0.99 -0.33 0.43 -0.138 0.0417 CYP2R1 intron 
rs561089663 11 14100539 G 1.00 0.00 0.41 4.79E-43 0.20 4.31E-11 0.0001 Not available in Ely datasets  0.078 0.5016 CYP2R1 intron 
rs10832218 11 14181174 C 0.20 0.20 -0.03 7.09E-32 -0.02 3.06E-10 0.0001 0.17 -0.12 0.20 -0.011 0.3662 CYP2R1 intron 
rs117206369 11 14335876 T 1.00 0.00 0.47 1.07E-48 0.23 1.10E-12 0.0002 1.00 -0.39 0.63 0.373 0.0004 CYP2R1 intron 
rs567876843 11 14414139 G 1.00 0.00 0.54 1.83E-180 0.54 3.35E-116 0.0027 0.99 0.34 0.35 0.193 0.0095 CYP2R1 intergenic 
rs148514005 11 14464878 T 0.01 0.01 -0.45 1.37E-184 -0.14 4.99E-15 0.0002 0.01 -0.01 0.97 -0.274 1.3E-06 CYP2R1 downstream 
rs571484036 11 14512559 A 1.00 0.00 -0.22 4.13E-16 -0.25 3.43E-20 0.0002 Not available in Ely datasets  -0.372 1.5E-05 CYP2R1 intron 
rs577185477 11 14612563 C 0.01 0.01 -0.38 1.624E-342 -0.15 7.55E-37 0.0007 0.01 -0.20 0.41 -0.260 1.7E-14 CYP2R1 intron 
rs554808052 11 14636390 C 1.00 0.00 0.35 5.41E-40 0.20 7.88E-13 0.0001 1.00 0.91 0.09 0.438 6.4E-07 CYP2R1 intron 
rs10832289 11 14669496 T 0.41 0.41 -0.07 2.03E-266 -0.09 0 0.0036 0.42 -0.08 0.14 -0.086 1.2E-46 CYP2R1 intron 
rs187443664 11 14768892 T 0.99 0.01 -0.11 3.49E-16 -0.08 1.52E-09 0.0001 0.99 -0.41 0.29 -0.167 0.0102 CYP2R1 intron 
rs188480917 11 14785870 G 0.01 0.01 -0.34 5.00E-275 -0.17 3.21E-37 0.0006 0.01 -0.37 0.12 -0.291 4.2E-21 CYP2R1 intron 
rs534042887 11 14818258 G 1.00 0.00 0.39 2.82E-82 0.19 2.21E-19 0.0002 1.00 0.69 0.22 0.255 0.0006 CYP2R1 intron 
rs532836473 11 14822853 G 1.00 0.00 0.44 4.90E-44 0.27 4.77E-17 0.0002 1.00 -0.16 0.78 0.268 0.0264 CYP2R1 intron 
rs201501563 11 14882470 T 0.12 0.12 -0.07 9.17E-67 -0.03 1.96E-18 0.0003 0.13 -0.07 0.54 -0.112 8.3E-14 CYP2R1   
rs117913124 11 14900931 A 0.03 0.03 -0.35 1.653E-775 -0.21 2.94E-107 0.0023 0.04 -0.27 0.04 -0.284 1.5E-55 CYP2R1 synonymous 
rs117576073 11 14912573 T 0.01 0.01 -0.11 1.22E-38 -0.17 1.40E-78 0.0007 0.01 -0.06 0.88 -0.135 3.2E-07 CYP2R1 5_prime_UTR 
rs150585703 11 14951216 G 1.00 0.00 0.48 7.16E-125 0.24 1.56E-27 0.0005 0.99 -0.16 0.72 0.276 7.3E-05 CYP2R1 intron 
rs574992951 11 16580958 C 0.99 0.01 0.09 4.04E-09 0.09 1.69E-09 0.0001 0.99 -0.43 0.22 0.089 0.1615 PLEKHA7 intron 
rs567415847 11 16854631 G 1.00 0.00 0.28 1.03E-14 0.30 1.88E-16 0.0004 Not available in Ely datasets  -0.236 0.1177 PLEKHA7 intron 
rs523583 11 66070146 C 0.47 0.47 0.01 5.58E-10 0.01 6.60E-12 0.0001 0.46 0.02 0.66 -0.002 0.6907 TMEM151A intergenic 
 
 35 
rs12803256 11 71132868 G 0.77 0.23 0.10 8.599E-407 0.09 1.64E-195 0.0027 0.76 0.06 0.30 -0.010 0.1527 FLJ42102 non_coding_transcript_exon 
rs536006581 11 71135151 G 0.01 0.01 -0.17 8.87E-35 -0.11 5.64E-14 0.0002 0.01 0.62 0.14 0.086 0.0640 FLJ42102 downstream 
rs574615332 11 71144427 A 1.00 0.00 -0.29 1.38E-28 -0.21 5.87E-15 0.0002 Not available in Ely datasets  -0.052 0.6369 FLJ42102 intron 
rs549940584 11 71222408 T 0.01 0.01 0.18 2.31E-72 0.15 1.93E-45 0.0006 0.00 -0.51 0.37 -0.054 0.0992 FLJ42102 intron 
rs200454003 11 71228990 T 0.26 0.26 -0.09 3.68E-256 -0.03 3.49E-21 0.0003 0.29 -0.01 0.93 0.021 0.0118 FLJ42102 intron 
rs10793129 11 75459865 A 0.09 0.09 0.02 1.64E-12 0.03 4.11E-13 0.0001 0.08 0.00 0.99 0.009 0.3882 
RP11-
21L23.4 intergenic 
rs1149605 11 76485216 C 0.17 0.17 0.02 7.34E-14 0.02 3.36E-15 0.0001 0.18 0.01 0.82 0.025 0.0018 
RP11-
21L23.4 intergenic 
rs964184 11 116648917 C 0.86 0.14 0.04 5.11E-44 0.04 1.30E-43 0.0004 0.85 0.05 0.53 0.015 0.0853 ZPR1 3_prime_UTR 
rs2847500 11 120114421 A 0.12 0.12 -0.02 7.79E-13 -0.02 1.93E-12 0.0001 0.12 -0.08 0.40 -0.003 0.7323 ZPR1 intron 
rs12317268 12 21352541 G 0.15 0.15 -0.02 9.15E-12 -0.02 9.20E-12 0.0001 0.14 0.13 0.09 -0.007 0.3751 SLCO1B1 intron 
rs9668081 12 38602911 T 0.47 0.47 0.01 5.38E-09 0.01 5.40E-09 0.0001 0.49 0.04 0.44 0.011 0.0601 FAM166AP9 upstream 
rs61937878 12 96371731 T 0.01 0.01 0.12 4.43E-22 0.10 5.63E-17 0.0001 0.01 0.15 0.57 -0.038 0.3136 HAL missence 
rs10859995 12 96375682 C 0.58 0.42 -0.04 7.03E-89 -0.04 3.03E-91 0.0008 0.58 -0.07 0.18 0.003 0.6502 HAL intron 
rs8018720 14 39556185 C 0.82 0.18 -0.03 4.04E-36 -0.03 4.10E-36 0.0003 0.84 -0.09 0.20 -0.046 2.6E-09 SEC23A missence 
rs261291 15 58680178 C 0.36 0.36 -0.02 2.89E-28 -0.02 2.46E-29 0.0002 0.37 -0.01 0.80 0.005 0.4603 LIPC intron 
rs1800588 15 58723675 T 0.21 0.21 -0.03 2.65E-36 -0.03 3.17E-37 0.0003 0.21 -0.10 0.12 -0.001 0.9433 LIPC intron 
rs17765311 15 63789952 C 0.34 0.34 -0.02 1.35E-13 -0.02 1.18E-13 0.0001 0.36 0.04 0.47 0.000 0.9895 AC007950.2 downstream 
rs62007299 15 77711719 A 0.71 0.29 -0.01 1.69E-11 -0.01 3.33E-11 0.0001 0.69 0.00 1.00 0.006 0.3478 PEAK1 intron 
rs8063706 16 11909552 T 0.27 0.27 0.01 3.64E-09 0.01 4.27E-09 0.0001 0.29 0.03 0.60 -0.013 0.0442 BCAR4 downstream 
rs77924615 16 20392332 A 0.20 0.20 -0.02 1.46E-10 -0.02 2.28E-10 0.0001 0.20 0.21 0.00 -0.002 0.8408 PDILT intron 
rs71383766 16 30930233 T 0.42 0.42 0.01 1.15E-09 0.01 1.86E-09 0.0001 0.45 0.03 0.58 -0.013 0.0457 FBXL19 upstream 
rs1800775 16 56995236 A 0.49 0.49 -0.02 1.56E-17 -0.02 1.57E-17 0.0001 0.46 -0.03 0.55 0.000 0.9495 CETP upstream 
rs2909218 17 66464546 T 0.79 0.21 0.02 2.81E-12 0.02 2.82E-12 0.0001 0.80 0.11 0.10 -0.003 0.6766 
RP11-
120M18.2 intron 
rs8091117 18 28919794 A 0.07 0.07 -0.02 1.03E-09 -0.02 9.48E-10 0.0001 0.07 0.04 0.69 -0.012 0.3137 DSG1 missence 
rs2037511 18 61366207 A 0.17 0.17 0.02 9.29E-10 0.02 8.35E-10 0.0001 0.16 0.01 0.87 -0.005 0.5735 SERPINB11 intron 
rs57631352 19 4338173 G 0.30 0.30 -0.01 1.48E-09 -0.01 1.50E-09 0.0001 0.31 0.00 0.94 0.010 0.1425 STAP2 intron 
rs73015021 19 11192915 G 0.12 0.12 0.02 1.15E-14 0.02 6.29E-14 0.0001 0.13 0.04 0.59 -0.001 0.9190 LDLR intergenic 
rs10500209 19 11979164 C 0.28 0.28 -0.01 6.18E-10 -0.01 2.73E-09 0.0001 0.28 -0.08 0.18 0.001 0.8869 LDLR missence 
rs58542926 19 19379549 T 0.08 0.08 0.03 8.57E-19 0.03 2.63E-19 0.0002 0.07 0.09 0.35 0.006 0.5708 TM6SF2 missence 
rs3814995 19 36342212 T 0.31 0.31 -0.01 2.83E-12 -0.02 1.08E-12 0.0001 0.32 -0.06 0.40 0.006 0.3743 NPHS1 missence 
rs1065853 19 45413233 T 0.08 0.08 0.03 8.32E-14 0.03 2.24E-14 0.0001 0.09 0.01 0.87 -0.008 0.4807 APOC1 upstream 
rs157595 19 45425460 G 0.61 0.39 -0.02 2.95E-14 -0.02 4.25E-15 0.0001 0.62 -0.14 0.01 -0.004 0.5361 APOC1 downstream 
rs112285002 19 48374320 T 0.16 0.16 0.06 1.77E-110 0.06 1.49E-90 0.0008 0.15 0.06 0.36 0.003 0.7114 SULT2A1 3_prime_UTR 
rs62130059 19 48461240 C 0.34 0.34 -0.03 9.25E-34 -0.02 2.64E-12 0.0001 0.32 -0.02 0.78 -0.003 0.7023 SULT2A1 intergenic 
rs10426 19 51517798 A 0.21 0.21 0.03 3.31E-26 0.03 1.59E-26 0.0002 0.20 0.03 0.63 -0.002 0.7403 KLK10 3_prime_UTR 
rs8103262 19 53065814 C 0.31 0.31 0.01 3.18E-09 0.01 6.80E-10 0.0001 0.30 -0.02 0.71 0.005 0.4445 ZNF808 intron 
rs6123359 20 52714706 G 0.11 0.11 0.03 7.74E-24 0.02 7.48E-14 0.0001 0.11 0.02 0.82 0.005 0.6144 
RP13-
379L11.3 intergenic 
rs6127099 20 52731402 T 0.28 0.28 -0.04 9.30E-62 -0.03 2.22E-32 0.0003 0.29 0.23 0.00 0.012 0.0892 
RP13-
379L11.3 intergenic 
rs2585442 20 52737123 G 0.25 0.25 0.03 6.87E-49 0.02 3.96E-23 0.0002 0.23 -0.05 0.42 -0.002 0.8239 
RP13-
379L11.3 intergenic 
rs2762942 20 52788925 A 0.94 0.06 0.05 7.99E-35 0.04 1.69E-23 0.0002 0.94 -0.08 0.52 -0.004 0.7518 
RP13-
379L11.3 intron 
rs2229742 21 16339172 C 0.10 0.10 -0.03 7.13E-16 -0.03 7.16E-16 0.0001 0.10 0.05 0.59 -0.009 0.3346 NRIP1 missence 
rs2074735 22 31535872 C 0.06 0.06 0.03 6.55E-12 0.03 7.12E-12 0.0001 0.07 -0.05 0.63 -0.023 0.0549 PLA2G3 missence 





Grey and white fonts are used to demarcate variants in the same locus. N: sample size; RSID: reference SNP cluster ID; CHR: chromosome; BP: base pair 792 
position of the variant according to human reference sequence (GRCh37), Hg19; EA: effect allele; EAF: effect allele frequency; MAF: minor allele frequency; β: 793 
per allele effect in standard deviations of standardized log-transformed 25OHD or 1,25 dihydroxyvitamin D; P: strength of evidence against the null hypothesis 794 
of no associations between variant and 25OHD (ie P-value) from standard linear regression; β.J: per allele effect estimated from joint analysis of conditionally 795 
associated snps; P.J: Strength of evidence against the null hypothesis of no association between the variant and 25OHD as estimated by conditional and joint 796 
genome-wide association analysis  (i.e. P-value);VAR.J: Proportion of variance explained by the conditionally associated variant; A.GENE: The name of the 797 
gene situated closest to variant that has smallest P-value of all conditionally independent variants present in the same locus; FUNCTION: Functional annotation 798 
of the conditionally independent variant. 799 
